Overcoming limitations of natural anticancer drugs by combining with artificial agents - PubMed (original) (raw)
Review
Overcoming limitations of natural anticancer drugs by combining with artificial agents
Mikhail V Blagosklonny. Trends Pharmacol Sci. 2005 Feb.
Abstract
During a billion years of evolution, living creatures have perfected cytotoxic agents to kill other organisms without killing themselves, thus providing us with antibiotics to kill bacteria without killing eukaryotic (e.g. human) cells. Some natural agents inhibit specifically most vital cellular structures and functions in cancer cells. However, nature was not creating antibiotics for cancer, and natural agents kill cancer cells precisely because they share targets with normal cells. To discriminate between particular cancer cells and normal cells, we can design or select artificial agents that are not necessarily lethal but are aimed either at cancer-specific targets or at dispensable and even unavailable (in cancer cells) targets. Using rational drug combinations, such selective agents can assist natural agents to eradicate cancer cells selectively.
Similar articles
- Development of novel alkylating drugs as anticancer agents.
Izbicka E, Tolcher AW. Izbicka E, et al. Curr Opin Investig Drugs. 2004 Jun;5(6):587-91. Curr Opin Investig Drugs. 2004. PMID: 15242245 Review. - Interaction of natural products with cell survival and signaling pathways in the biochemical elucidation of drug targets in cancer.
Qurishi Y, Hamid A, Majeed R, Hussain A, Qazi AK, Ahmed M, Zargar MA, Singh SK, Saxena AK. Qurishi Y, et al. Future Oncol. 2011 Aug;7(8):1007-21. doi: 10.2217/fon.11.69. Future Oncol. 2011. PMID: 21823895 Review. - [Anticancer drugs and pharmacologic actions].
Ogawa M. Ogawa M. Nihon Rinsho. 1997 May;55(5):1017-23. Nihon Rinsho. 1997. PMID: 9155146 Review. Japanese. - Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
Mao CY, Hua HJ, Chen P, Yu DC, Cao J, Teng LS. Mao CY, et al. Hepatobiliary Pancreat Dis Int. 2009 Jun;8(3):282-7. Hepatobiliary Pancreat Dis Int. 2009. PMID: 19502169 - [Result of antineoplastic agents screening: 7th report].
[No authors listed] [No authors listed] Gan To Kagaku Ryoho. 1998 Mar;25 Suppl 2:147-392. Gan To Kagaku Ryoho. 1998. PMID: 9551093 Japanese. No abstract available.
Cited by
- Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-_b_-Poly(Caprolactone) Polymeric Micelles Encapsulating Fenbendazole and Rapamycin in Ovarian Cancer.
Shin YB, Choi JY, Shin DH, Lee JW. Shin YB, et al. Int J Nanomedicine. 2023 May 1;18:2209-2223. doi: 10.2147/IJN.S394712. eCollection 2023. Int J Nanomedicine. 2023. PMID: 37152471 Free PMC article. - Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death.
Raimondo S, Naselli F, Fontana S, Monteleone F, Lo Dico A, Saieva L, Zito G, Flugy A, Manno M, Di Bella MA, De Leo G, Alessandro R. Raimondo S, et al. Oncotarget. 2015 Aug 14;6(23):19514-27. doi: 10.18632/oncotarget.4004. Oncotarget. 2015. PMID: 26098775 Free PMC article. - A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome.
El-Sayed S, Freeman S, Bryce RA. El-Sayed S, et al. Molecules. 2022 Sep 21;27(19):6213. doi: 10.3390/molecules27196213. Molecules. 2022. PMID: 36234744 Free PMC article. Review. - My battle with cancer. Part 1.
Blagosklonny MV. Blagosklonny MV. Oncoscience. 2024 Jan 3;11:1-14. doi: 10.18632/oncoscience.593. eCollection 2024. Oncoscience. 2024. PMID: 38188499 Free PMC article. Review. - Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.
Amelio I, Landré V, Knight RA, Lisitsa A, Melino G, Antonov AV. Amelio I, et al. Oncotarget. 2015;6(12):9646-56. doi: 10.18632/oncotarget.3917. Oncotarget. 2015. PMID: 25991664 Free PMC article. Review.